Format

Send to

Choose Destination
Neuropsychopharmacology. 2016 Apr;41(5):1191-8. doi: 10.1038/npp.2015.282. Epub 2015 Sep 11.

Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury.

Author information

1
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
2
Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Brigham and Women's Hospital and Harvard Medical School, Boston MA, USA.
3
Department of Family Medicine and Public Health, Biostatistics Research Center, University of California, San Diego, CA, USA.
4
Department of Psychiatry, Neuropsychology Program, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
5
Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.
6
Department of Neurosurgery, Stanford University/Lucile Packard Children's Hospital, Stanford CA, USA.
7
Department of Psychiatry, University of California, San Diego, CA, USA.
8
Department of Neurosurgery, College of Medicine/Mayfield Clinic, Neuroscience Institute, University of Cincinnati, Cincinnati, OH, USA.
9
Department of Psychiatry, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
10
Laureate Institute for Brain Research, Tulsa, OK, USA.
11
Department of Psychiatry and Department of Family Medicine and Public Health, University of California, San Diego, CA, USA.

Abstract

We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.

PMID:
26361060
PMCID:
PMC4793116
DOI:
10.1038/npp.2015.282
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center